New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ceftriaxone sodium 1.079 g equivalent to 1 g ceftriaxone (anhydrous) - powder for injection - 1 g - active: ceftriaxone sodium 1.079 g equivalent to 1 g ceftriaxone (anhydrous) - infections caused by pathogens sensitive to ceftriaxone e.g.: - sepsis; - meningitis; - abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts); - infections of the bones, joints, soft tissue, skin and of wounds; - infections in patients with impaired defence mechanisms; - renal and urinary tract infections; - respiratory tract infections, particularly pneumonia, and ear, nose and throat infections; - genital infections, including gonorrhoea. - perioperative prophylaxis of infections.

Malta - English - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - ceftriaxone - powder for solution for injection/infusion - ceftriaxone 1000 mg - antibacterials for systemic use

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - ceftriaxone disodium 1079,27 mg/3,5 ml - eq. ceftriaxone 1000 mg - powder and solvent for solution for injection - 1 g - 3,5 ml - ceftriaxone (di)sodium - ceftriaxone

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ceftriaxone sodium 596.5mg (present as 0.5965g ceftriaxone na*3.5h2o. eq 0.53965g of ceftriax na anh or 0.5g ceftriaxone anhyd);   - powder for injection - 500 mg - active: ceftriaxone sodium 596.5mg (present as 0.5965g ceftriaxone na*3.5h2o. eq 0.53965g of ceftriax na anh or 0.5g ceftriaxone anhyd)  

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - ceftriaxone as sodium - powder for solution for inj/inf - ceftriaxone as sodium 1000 mg/vial - ceftriaxone - ceftriaxone - * ceftriaxone-fresenius is indicated for the treatment of the following infections in adults and children including term neonates (from birth) :- bacterial meningitis- community acquired pneumonia- hospital acquired pneumonia- acute otitis media- intra-abdominal infections- complicated urinary tract infections (including pyelonephritis)- infections of bones and joints- complicated skin and soft tissue infections- gonorrhoea- syphilis- bacterial endocarditis* ceftriaxone-fresenius may be used:- for treatment of acute exacerbations of chronic obstructive pulmonary disease in adults- for treatment of disseminated lyme borreliosis (early (stage ii) and late (stage iii)) in adults and children including neonates from 15 days of age.- for pre-operative prophylaxis of surgical site infectionsin the management of neutropenic patients with fever that is suspected to be due to a bacterial infectionin the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above* ceftriaxone-fresenius should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum.* consideration should be given to official guidelines on the appropriate use of antibacterial agents.

Israel - English - Ministry of Health

vitamed pharmaceutical industries ltd - ceftriaxone as disodium hemiheptahydrate - powder for solution for injection - ceftriaxone as disodium hemiheptahydrate 1.0 g/vial - ceftriaxone - ceftriaxone vit is indicated for the treatment of the following infections in adults andchildren including term neonates (from birth):-bacterial meningitis- community acquired pneumonia-hospital acquired pneumonia-acute otitis media-intra-abdominal infections-complicated urinary tract infections (including pyelonephritis)-infections of bones and joints-complicated skin and soft tissue infections-gonorrhoea-syphilis-bacterial endocarditisceftriaxone vit may be used:- for treatment of acute exacerbations of chronic obstructive pulmonary diseasein adults- for treatment of disseminated lyme borreliosis (early (stage ii) and late (stageiii) in adults and children including neonates from 15 days of age.- for pre-operative prophylaxis of surgical site infections-in the management of neutropenic patients with fever that is suspected to be dueto a ceftriaxone – susceptible bacterial infection- in the treatment of patients with bacteraemia that occurs in association with, oris suspected to be associated with, any of the infections listed aboveceftriaxone vit should be co-administered with other antibacterial agents whenever thepossible range of causative bacteria would not fall within its spectrum.

Israel - English - Ministry of Health

pharmalogic ltd - ceftriaxone as sodium - powder for solution for inj/inf - ceftriaxone as sodium 1 g/vial - ceftriaxone - ceftriaxone - ceftriaxone panpharma is indicated for the treatment of the following infections in adults and children including term neonates (from birth):- bacterial meningitis- community acquired pneumonia- hospital acquired pneumonia- acute otitis media- intra-abdominal infections- complicated urinary tract infections (including pyelonephritis)- infections of bones and joints- complicated skin and soft tissue infections- gonorrhoea- syphilis- bacterial endocarditisceftriaxone panpharma may be used:- for treatment of acute exacerbations of chronic obstructive pulmonary disease in adults- for treatment of disseminated lyme borreliosis (early (stage ii) and late (stage iii) in adults and children including neonates from 15 days of age.- for pre-operative prophylaxis of surgical site infections- in the management of neutropenic patients with fever that is suspected to be due to a ceftriaxone- susceptible bacterial infection- in the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above ceftriaxone panpharma should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum.consideration should be given to official guidelines on the appropriate use of antibacterial agents.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - ceftriaxone disodium - eq. ceftriaxone 1000 mg - powder for solution for injection/infusion - 1 g - ceftriaxone (di)sodium - ceftriaxone

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - ceftriaxone disodium - eq. ceftriaxone 2000 mg - powder for solution for infusion - 2 g - ceftriaxone (di)sodium - ceftriaxone

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - ceftriaxone disodium 2158,54 mg - eq. ceftriaxone 2000 mg - powder for solution for infusion - 2 g - ceftriaxone (di)sodium - ceftriaxone